Skip to content
Screener

Alumis Inc. ALMS Business Segments — Other Research And Development Expense

Similar metrics at other companies

Dogwood Therapeutics logo
DWTXSingle Reportable — Other Research And Development Expense
$585.61K+33.4%
UroGen Pharma logo
URGNSingle Reportable — Other Research And Development Expense
$258K+119%
Celldex Therapeutics logo
CLDXSingle Reportable — Other Research And Development Expense
$6.14M+71.1%
Lantheus Holdings logo
LNTHReportable — Other Research And Development Expense
$29.73M-18.7%
Solid Biosciences Inc. logo
SLDBExternal Research And Development Other — Other Research And Development Expense
$1.98M-36.4%
TG Therapeutics logo
TGTXOther Research And Development Expense
$87.27M+218%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
External costs
CROs, CMOs and clinical trials40,92865,072
Professional consulting services6,8046,403
Other research and development costs2,3702,296
Internal costs
Personnel-related costs26,06517,659
Facilities and overhead costs5,3735,192
Total research and development expense81,54096,622

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s business segments — other research and development expense?
Alumis Inc. (ALMS) reported business segments — other research and development expense of $2.37M in Q1 2026.
How has Alumis Inc.'s business segments — other research and development expense changed year-over-year?
Alumis Inc.'s business segments — other research and development expense increased by 3.2% year-over-year, from $2.3M to $2.37M.
What is the long-term trend for Alumis Inc.'s business segments — other research and development expense?
Over 2 years (2023 to 2025), Alumis Inc.'s business segments — other research and development expense has grown at a -10.9% compound annual growth rate (CAGR), from $11.46M to $9.1M.
What does business segments — other research and development expense mean?
Encompasses miscellaneous research and development expenditures that do not fall into specific categories like personnel, facilities, or clinical trials. This metric provides visibility into the ancillary costs required to sustain the broader R&D infrastructure.

Ask your AI about Alumis Inc.'s business segments — other research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude